Intestinal oxygenation therapy
Intestinal oxygenation therapy using oxygen carriers and prodrugs converts the intestinal environment to an aerobic state, effectively inhibiting anaerobic bacterial growth and reducing toxicity, addressing the inefficiencies of existing treatments.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- LPOXY THERAPEUTICS INC
- Filing Date
- 2021-03-31
- Publication Date
- 2026-07-22
AI Technical Summary
Existing treatments for intestinal anaerobic infections, such as hyperbaric oxygen therapy, are inefficient, inaccessible, and pose risks due to narrow therapeutic indices, and do not effectively convert the anaerobic intestinal environment to an aerobic one.
Intestinal oxygenation therapy (EAT) using oxygen carrier molecules, oxygen-containing mixtures, oxygen prodrugs, and oxygen-evolving compounds to deliver oxygen to the intestinal tract, creating an aerobic environment that inhibits anaerobic bacterial growth and reduces toxicity.
EAT effectively converts the intestinal environment to an aerobic state, inhibiting anaerobic bacterial growth and reducing toxicity, providing a safe and accessible treatment for infections like Clostridioides difficile, foodborne illnesses, and inflammatory bowel disease.
Smart Images

Figure 0007893747000002 
Figure 0007893747000003 
Figure 0007893747000004